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Antibodies that neutralize infectivity of malaria sporozoites target the central repeat region
of the circumsporozoite (CS) protein, which in Plasmodium falciparum is comprised
primarily of 30–40 tandem NANP tetramer repeats. We evaluated immunogenicity
of an alum-adsorbed (NANP)6 peptide conjugated to an outer membrane protein
complex (OMPC) derived from Neisseria meningitidis, a carrier protein used in a
licensed Haemophilus influenzae pediatric vaccine. Mice immunized with (NANP)6-OMPC
adsorbed to Merck’s alum adjuvant (MAA), with or without Iscomatrix® as co-adjuvant,
developed high levels of anti-repeat peptide antibody that inhibited in vitro invasion of
human hepatoma cells by transgenic P. berghei sporozoites that express P. falciparum CS
repeats (PfPb). Inhibition of sporozoite invasion in vitro correlated with in vivo resistance to
challenge by the bites of PfPb-infected mosquitoes. Challenged mice had >90% reduction
of hepatic stage parasites as measured by real-time PCR, and either sterile immunity,
i.e., no detectable blood stage parasites, or delayed prepatent periods which indicate
neutralization of a majority, but not all, sporozoites. Rhesus macaques immunized with
two doses of (NANP)6-OMPC/MAA formulated with Iscomatrix® developed anti-repeat
antibodies that persisted for ∼2 years. A third dose of (NANP)6-OMPC/MAA+ Iscomatrix®
at that time elicited strong anamnestic antibody responses. Rhesus macaque immune
sera obtained post second and third dose of vaccine displayed high levels of sporozoite
neutralizing activity in vitro that correlated with presence of high anti-repeat antibody
titers. These preclinical studies in mice of different MHC haplotypes and a non-human
primate support use of CS peptide-OMPC conjugates as a highly immunogenic platform
to evaluate CS protective epitopes. Potential pre-erythrocytic vaccines can be combined
with sexual blood stage vaccines as a multi-antigen malaria vaccine to block invasion and
transmission of Plasmodium parasites.
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INTRODUCTION
Malaria caused by the parasite Plasmodium falciparum is con-
sidered one of the most prevalent and deadliest of diseases.
The complexity of the Plasmodium life cycle, which involves
multiple parasite stages in the mosquito vector and in the mam-
malian host, necessitates a multipronged control effort, ide-
ally involving a combination of chemotherapy, vector control,
and vaccines. Despite the fact that 40% of the world’s pop-
ulation is at risk of malaria, with 300–500 million cases and
1 million deaths each year, there is no licensed malaria vaccine
available.
One of the lead vaccine candidates in clinical trials is the cir-
cumsporozoite (CS) protein which is a major surface protein
of the infective sporozoite. A Phase III trial is in progress of
a CS-based pediatric malaria vaccine RTS,S which can protect
35–40% of African infants against clinical disease (Agnandji
et al., 2011). Immunization with RTS,S in a potent adjuvant for-
mulation elicited sterile immunity in 30–40% of malaria-naïve
volunteers, however, only transient protection against infection
was obtained in African adults (Bojang et al., 2001; Kester et al.,
2009). Protection correlated with high levels of anti-repeat anti-
bodies and CS-specific CD4+ T cells (Kester et al., 2009; Olotu
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et al., 2010, 2011). While these studies support the feasibility of a
CS-based subunit vaccine, efforts continue to increase immuno-
genicity and efficacy of malaria vaccines using new adjuvant and
delivery platforms.
The first trial of a malaria peptide vaccine directly targeting the
CS repeats was the peptide-conjugate vaccine using tetanus toxoid
(TT) as carrier protein, (NANP)3-TT, which elicited anti-repeat
antibodies that protected a small number of immunized volun-
teers challenged by exposure to the bites of P. falciparum-infected
mosquitoes (Herrington et al., 1987). These studies provided
proof-of-principle that a CS repeat peptide vaccine could elicit
protective immunity in humans, however, the magnitude of anti-
repeat antibody responses in this first clinical trial were subop-
timal. The humoral response was dose dependent and a major
limitation of the vaccine was the low density of peptide that
could be conjugated to the TT carrier. The outer membrane pro-
tein complex (OMPC) of Neisseria meningitidis is an attractive
carrier protein as it provides high density peptide conjugation.
OMPC has a clinical track record as a carrier for polysaccha-
rides in a pediatric Haemophilis influenzae type b (Hib) vaccine,
PedvaxHIB® (Merck), used safely in millions of infants world-
wide (Zhou et al., 2002). The use of a carrier with prior appli-
cations in commercial pediatric vaccines would be particularly
attractive for a malaria vaccine, as infants suffer the majority of
the one million malaria deaths in Africa, and scale-up produc-
tion, safety, and acceptability have been previously established. In
previous studies, we have shown that a conjugate of OMPC to a
P. falciparum gamete/ookinete protein, Pfs25, elicited high titers
of transmission blocking antibodies in mice and rhesus macaques
that reduced mosquito infection (Wu et al., 2006).
In the initial assessment of OMPC as carrier for P. falci-
parum CS repeats, synthetic peptide containing variable num-
bers of the P. falciparum NANP tetramer were conjugated to
OMPC and tested with various adjuvants for immunogenicity in
mice and rhesus macaques. In inbred strains of mice, (NANP)6-
OMPC/Merck alum adjuvant (MAA) immunization elicited high
levels of anti-repeat antibodies that neutralized sporozoite infec-
tivity in vitro and in vivo. In rhesus macaques, (NANP)6-
OMPC/MAA formulated with Iscomatrix® elicited anti-repeat
antibodies that persisted for two years following a prime and
boost immunization and strong anamnestic antibody responses
were obtained following a second boost. The sporozoite neutral-
izing activity in the rhesus macaque sera correlated with levels of
anti-repeat antibodies and neutralizing activity could be inhib-
ited by presence of repeat peptide in a peptide competition assay.
These promising studies in inbred and outbred animals support
efforts to develop OMPC conjugates containing multiple malaria
antigens to elicit immune responses that effectively block trans-
mission of the parasite to the mammalian host as well as to the
mosquito vector.
MATERIALS AND METHODS
SYNTHETIC PEPTIDES
The P. falciparum CS repeat tetramers, (NANP)3 and (NANP)6,
were synthesized as bromoacetylated peptides with the lat-
ter peptide also synthesized having the bromoacetyl group
at the C-terminus. A spacer 6-aminohexanoic acid (Aha)
was incorporated between the repeats and BrAc. The non-
bromoacetylated containing terminus of the peptide was blocked
with an N-acetyl or carboxamide group to give final constructs:
BrAcAha(NANP)3NH2: BrAc-Aha-NANPNANPNANP-NH2
BrAcAha(NANP)6NH2: BrAc-Aha-NANPNANPNANPNAN
PNANPNANP-NH2
Ac(NANP)6LysAhaBrAc-NH2: Ac-NANPNANPNANPNANP
NANPNANP-Lys (Aha-BrAc)-NH2
Peptides were cleaved from the resin with a mixture of 95%
TFA, 2.5% water, and 2.5% triisopropylsilane. The crude pep-
tide product was lyophilized to dryness, re-suspended in 50%
acetic acid and water (v:v), and purified by preparative RP-HPLC.
Fractions were analyzed by LC/MS HPLC. Fractions with cor-
rect mass and >95% homogeneity by peak area were pooled and
lyophilized to dryness.
CONJUGATIONOF CS REPEAT PEPTIDES TO OMPC
OMPC was obtained from Merck Manufacturing Division (West
Point, PA). A portion of OMPC surface amines were asepti-
cally thiolated using N-acetylhomocysteinethiolactone (Aldrich,
St. Louis, MO.) in N2-sparged borate buffered saline (25mM
sodium borate, pH 8.5, 0.15M NaCl), as previously described
(Wu et al., 2006), with the final thiolated OMPC re-suspended
in N2-sparged 25mM sodium borate, pH 8.5, 0.15M NaCl. Free
thiol content was determined by Ellman assay and measured thiol
content was between 0.2 and 0.3µmol/mL. Peptides were re-
suspended in N2-sparged borate buffered saline (25mM borate,
0.15M sodium chloride, pH 8.5) at 5mg/mL and 0.22µm fil-
tered. Peptides were mixed with the thiolated OMPC solution
at a final 1.5-fold molar excess of peptide BrAc to total OMPC
thiol. The reaction was protected from light and incubated at
ambient temperature for∼22 h. Residual free OMPC thiol groups
were quenched with a 5-fold molar excess of N-ethylmaleimide
for 4 h at ambient temperature. Quenched conjugates were dia-
lyzed exhaustively against borate buffered saline dialysis buffer in
Spectra-Por 100,000 Da MWCO dialysis units (Spectrum Labs,
RanchoDominguez, CA). Any aggregated material in the dialyzed
product was removed by centrifugation at 2,280 × g for 5min
at 4◦C.
CONJUGATE ANALYSIS
Total protein content was determined by a modified Lowry
assay (Markwell et al., 1978) and aliquots of conjugate
and control OMPC (thiol activated OMPC, N-ethylmalemide
quenched, and dialyzed) were analyzed by quantitative amino
acid analysis (AAA). Peptide to OMPC molar ratios were
determined from quantitation of the unique residue S-
carboxymethylhomocysteine (SCMHC) which was released upon
acid hydrolysis of the nascent peptide-OMPC bond (Nahas et al.,
2008). The OMPC-specific concentration was determined from
hydrolysis-stable residues which were absent from the peptide
sequence and thus unique to OMPC protein. Assuming 1 mol of
peptide for every mol SCMHC, the ratio of SCMHC/OMPC was
thus equivalent to the peptide/OMPC content. The mass loading
of peptide could be calculated from this ratio using the peptide
molecular weight and an average OMPC mass of 40,000,000 Da.
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The covalent nature of the conjugation was qualitatively con-
firmed by SDS-PAGE analysis using 4–12% Bis-Tris NuPAGE gels
(Invitrogen, Carlsbad, CA) where an upward shift in mobility was
observed for the Coomassie-stained conjugate bands relative to
control activated and quenched OMPC (data not shown).
ADJUVANT FORMULATION
Conjugates were adsorbed to Merck’s amorphous alu-
minum hydroxyphosphate sulfate adjuvant (MAA) (Merck
Manufacturing Division, West Point, PA) to give a final alu-
minum concentration of 0.45mg/ml. The Al3+/dose were
0.045mg for mice and 0.225mg for rhesus macaques. In some
experiments, a saponin-based adjuvant, Iscomatrix® (CSL,
Melbourne, VIC, Australia), was added to the MAA-adsorbed
peptide conjugate to give a final concentration of 0.025mg Isco
units/mL for mouse preparation (2.5µg/dose) and 0.1mg Isco
units /mL for the rhesus macaque preparation (50mcg/dose).
MURINE IMMUNOGENICITY STUDIES
All murine studies were approved by IACUC at New York
University School of Medicine and Merck Research Laboratories
(West Point, PA). Female Balb/c mice (Taconic Farms) or C57Bl/6
mice (Jackson Labs, Me), 6–8 weeks of age (n = 5–10/group)
were given three 4µg doses of conjugated peptide on days 0,
14, and 28 by hind leg intramuscular (IM) injection. Three
constructs were tested that differed in number of repeats and
peptide orientations: conjugation to N-terminus of (NANP)3 or
(NANP)6 peptide [OMPC-Aha(NANP)3NH2/MAA and OMPC-
Aha (NANP)6/MAA, respectively], and C-terminal conjugation
of (NANP)6-OMPC/MAA. The (NANP)6-OMPC/MAA C-
terminal conjugation was evaluated with and without the
addition of Iscomatrix® as co-adjuvant. Control mice were
immunized with activated/quenched but non-conjugated OMPC
adsorbed to MAA. In an additional experiment, mice received
two doses of OMPC/MAA prior to immunization with single
dose of (NANP)6-OMPC/MAA. Blood samples were obtained for
serum prior to each immunization and at various time points post
second dose to measure antibody persistence. Serum was stored
at −20◦C until assayed.
RHESUSMACAQUES IMMUNOGENICITY STUDIES
Adult Macaca mulatta rhesus macaques of Indian origin, 6 years
of age at the start of the study, were housed at an AAALAC
approved facility at New Iberia Research Center (NIRC), New
Iberia, LA. Rhesus macaque studies were approved by IACUC
at NIRC and Merck Research Laboratories. Groups of three
adult rhesus macaques were given three 4µg doses of (NANP)6-
OMPC/MAA on days 0, 70, and 732 by deltoid IM injection. The
MAA adsorbed peptide conjugate was tested with and without
Iscomatrix® as co-adjuvant. Blood was drawn intravenously at
days 1, 35, 69, 84, 140, 200, 300, 365, 732, and 760. Sera was gen-
erated from the blood samples using serum separators and stored
at −70◦C.
SEROLOGIC ASSAYS
Enzyme-linked immunoadsorbent assay (ELISA) was carried
out to measure anti-repeat antibodies using as coating antigen
either (NANP)3 tetrabranched peptide (Nardin et al., 1995) or
R32, an E. coli expressed recombinant protein containing 32
tetramer repeats (Young et al., 1985). Briefly, 96-well plates (Nunc
Immuno Plate, MaxiSorp or Immunolon 2HB) were coated with
100 ng/well of recombinant R32 protein or with 1µg/ml tetra-
branched (NANP)3 peptide. Murine or rhesus macaque sera were
tested at 2-fold dilutions starting at 1:80 dilution. MAB 2A10,
specific for P. falciparum CS repeats, was titrated on each plate
as a positive control. Plates were washed using PBS with 0.05%
Tween20 prior to addition of species specific peroxidase-labeled
anti-IgG antibody (Sigma-Aldrich, St. Louis, MO; or Kirkegaard,
Perry Laboratories, Gaithersburg, MD). Plates were subsequently
washed after incubation using PBS/0.05% Tween20. Color devel-
opment was accomplished using ABTS 1:1 (Fisher) and plates
read at wavelength A405 nm. Antibody endpoints were determined
based on a cut-off OD greater than three times OD in BSA-coated
wells. The ug/ml of anti-repeat antibody was determined by linear
regression based on titration of MAB 2A10.
Indirect immunofluorescence (IFA) was carried out using
two-fold dilutions of pooled mouse sera, or individual rhesus
macaques sera incubated on multiwell slides containing air-dried
P. falciparum sporozoites (Othoro et al., 2009). Following wash-
ing, slides were reacted with species-specific FITC-labeled anti-Ig
antibodies (Kirkegaard, Perry Laboratories; Gaithersburg, MD).
Slides were coded and the endpoint titer was defined as the high-
est sera dilution giving sporozoites with unequivocal positive
fluorescence.
The circumsporozoite precipitin (CSP) reaction is a terminal
precipitin that forms on viable sporozoites incubated in immune
serum due to antibody cross-linking of the surface CS protein
(Vanderberg et al., 1969; Cochrane et al., 1976). CSP reactions
were carried out using PfPb sporozoites, a transgenic P. berghei
strain that expresses P. falciparum CS repeats (Persson et al.,
2002). Equal volumes of sporozoites (1 × 106/ml) and 2-fold
dilutions of immune sera were incubated for 45min at 37◦C.
The endpoint titer was defined as the last serum dilution giving
2+ CSP reactions in a total of 20 sporozoites when examined by
phase-contrast microscopy.
TRANSGENIC SPOROZOITE NEUTRALIZATION ASSAY (TSNA)
The presence of functional inhibitory antibodies was determined
in vitro using PfPb sporozoites, transgenic P. berghei parasites
expressing P. falciparum repeats (Kumar et al., 2004; Othoro et al.,
2009). PfPb sporozoites (2 × 104) were incubated with serial dilu-
tions of murine or rhesus macaque sera for 40min on ice prior
to addition to 24 well plates containing confluent HepG2 cells.
Controls included sporozoites incubated with 25µg/ml of MAB
2A10, specific for P. falciparum CS repeats or MAB 3D11 specific
for P. berghei CS repeats, or with medium only. Plates were cul-
tured for 48 h at 37◦C and 5% CO2, harvested and total RNA
extracted and reverse transcribed. Parasite levels were quantitated
by real-time qPCR using primers for parasite 18S ribosomal RNA,
as previously described (Bruna-Romero et al., 2001; Othoro et al.,
2009).
CHALLENGE BY EXPOSURE TO BITES OF PfPb-INFECTED MOSQUITOES
Immunized and naïve C57Bl/6 mice were anesthetized and
challenged by exposure for 15min to the bites of 10–20
Anopheles stephansi mosquitoes infected with PfPb transgenic
rodent parasites expressing the P. falciparum CS repeats. Forty
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hours post challenge, mice were sacrificed, livers removed, and
RNA extracted for measurement of parasite burden by qPCR,
as described for TSNA. The remaining mice where followed
by microscopy using daily Giemsa-stained blood smears to
determine presence of blood stage parasites. Mice that remained
blood stage parasite negative for 14 days post challenge were
considered to have sterile immunity.
RESULTS
IMMUNOGENICITY OF (NANP)6-OMPC CONJUGATE IN INBRED
STRAINS OF MICE
Initial studies carried out in BALB/c mice established the number
of repeats and peptide orientation required for optimal immuno-
genicity of the peptide-OMPC conjugates. A peptide-OMPC
conjugate containing six NANP repeats, (NANP)6-OMPC, was
found to elicit higher anti-repeat antibody titers than the con-
jugate containing three NANP repeats, (NANP)3-OMPC. Peptide
orientation did not affect immunogenicity, as no difference was
observed between N- or C-terminal conjugation of the (NANP)6
peptide to OMPC (data not shown). All subsequent studies were
therefore carried out using an (NANP)6-OMPC conjugate.
Balb/c mice were immunized on days 0, 14, and 28 by IM
injection of 4µg (NANP)6-OMPC (total peptide in conjugate)
adsorbed to MAA (Merck amorphous aluminum hydroxphos-
phate sulfate), with or without Iscomatrix® as co-adjuvant. All
conjugates were dosed based on the specific peptide content
as measured by quantitative AAA. Following the third dose of
(NANP)6-OMPC/MAA, peak anti-repeat antibody concentra-
tions of ∼1,200µg/ml were measured by ELISA (Figure 1). The
magnitude of the antibody response was comparable using either
(NANP)3 peptide or recombinant R32 protein coated plates in the
ELISA.
FIGURE 1 | Immunogenicity of (NANP)6-OMPC in BALB/c. Mice
(n = 10/group) were immunized with three doses of (NANP)6-OMPC/MAA
with (open bars) or without (hatched bars) Iscomatrix®. ELISA used either
recombinant protein R32 (left panel), or (NANP)3 peptide (right panel).
Antibody levels obtained with freshly prepared (NANP)6-OMPC/MAA
(hatched bars) were compared with peptide-conjugate stored for 2 years at
4◦C (black bars).
Addition of the Iscomatrix® co-adjuvant to the MAA formu-
lation did not significantly increase immunogenicity (Figure 1,
open bar). In the second experiment, BALB/c mice gave com-
parable results when immunized with the same preparation of
peptide conjugate which had been stored at 4◦C for ∼2 years
(Figure 1, black bars). The µg/ml of repeat specific antibody in
Experiment I was 1,130µg/ml and in Experiment II 1,110µg/ml,
corresponded to geometric mean endpoint titers (GMT) of
359,480 and 551,090, respectively, when measured against
(NANP)3 peptide. All subsequent murine studies were car-
ried out using the (NANP)6-OMPC/MAA formulation without
Iscomatrix®.
Humoral immune responses in a second inbred strain,
C57Bl/6, demonstrated that the high level of anti-repeat antibody
induced by (NANP)6-OMPC/MAA was not strain depen-
dent and was highly reproducible (Figure 2). In two indepen-
dent experiments in C57Bl/6 mice, 100% seroconversion was
obtained following a single dose of (NANP)6-OMPC /MAA,
with 17–21µg/ml of anti-repeat antibody (black solid bars vs.
black hatched bars), corresponding to 12,607 vs. 6,967 GMT
when expressed as endpoint titers (gray solid bars vs. gray
hatched bars). A booster injection on day 14 elicited a 6–12-
fold increase in the anti-repeat titers. Peak antibody responses
were obtained following the third dose, with an additional 2–
5-fold increase to 502–516µg/ml of anti-repeat antibody, corre-
sponding to GMT 376,405 and 305,736 in Experiment 1 and 2,
respectively. The antibodies elicited by (NANP)6-OMPC reacted
with native CS on sporozoites. The sera from mice immu-
nized with either fresh or stored peptide-conjugate reacted with
air-dried P. falciparum sporozoites with ∼104 IFA titers. The
FIGURE 2 | Immunogenicity of (NANP)6-OMPC/MAA in C57Bl/6 mice.
Kinetics of anti-repeat antibody response shown for two experiments (solid
bars Experiment I, hatched bars Experiment II). Antibody concentration is
shown as µg/ml (left axis) or geometric mean titers (GMT) (right axis), as
measured in ELISA using either R32 (black bars) or (NANP)3 peptide
(gray bars) as coating antigen.
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immune sera also elicited high CSP titers (1:125) when incu-
bated with viable PfPb sporozoites expressing P. falciparum CS
repeats, indicating that the antibodies elicited by the peptide con-
jugates effectively cross-linked the surface CS protein on viable
sporozoites.
OMPC is a carrier for bacterial capsular polysaccharide in a
Haemophilus influenzae type b pediatric vaccine (PedvaxHIB®),
which is widely used to prevent childhood bacterial meningi-
tis. Therefore, a proportion of infants might have antibody to
the OMPC carrier that could positively or negatively modu-
late the response to (NANP)6-OMPC vaccine. To test whether
anti-OMPC antibodies modulate the anti-repeat response, mice
were primed with two doses of OMPC (anti-OMPC GMT 5,120)
followed by a single dose of (NANP)6-OMPC/MAA.
The kinetics and magnitude of the anti-repeat antibody in
OMPC-immunized mice were comparable to responses elicited
when (NANP)6-OMPC was used to immunize mice without
pre-existing anti-OMPC antibodies (Figure 3). The pre-existing
anti-OMPC antibody also did not alter the persistence of the
anti-repeat antibody response, with GMT of 761 and 905 at
160 days post the single dose of (NANP)6-OMPC/MAA in mice
with or without pre-existing anti-OMPC antibodies, respectively.
Importantly, the development of malaria-specific memory B cells
was also not affected, as exposure to the bites of PfPb infected
mosquitoes at day 160 increased anti-repeat antibody responses
in both the OMPC-primed and non-primed mice. These find-
ings suggest that the potential presence of anti-OMPC antibodies
will not inhibit response to a malaria peptide-OMPC conjugate.
In addition, the findings also suggest that the vaccine induced
FIGURE 3 | Immunization of mice with pre-existing anti-OMPC
antibody. A single dose of (NANP)6−OMPC/MAA was given to naïve
C57Bl/6 (open triangle) or to mice previously immunized with two doses of
OMPC/MAA with anti-OMPC GMT 5120 (data not shown) at time of
immunization (closed triangle). All groups were exposed to the bites of
irradiated PfPb infected mosquitoes on day 160.
anti-repeat antibody response can be boosted by exposure to the
bites of malaria-infected mosquitoes, providing the potential for
continued boosters in malaria endemic areas.
SPOROZOITE NEUTRALIZING ANTIBODY IN SERA OF (NANP)6-OMPC
IMMUNIZED MICE
The high titers of anti-repeat antibody elicited by immunization
with (NANP)6-OMPC/MAA were found to be functional when
tested in an in vitro sporozoite neutralizing assay using trans-
genic P. berghei sporozoites expressing P. falciparum CS repeats
(PfPb) (Kumar et al., 2004). When PfPb sporozoites were pre-
incubated with serum from (NANP)6-OMPC/MAA immunized
BALB/cmice prior to addition toHepG2 cell cultures, the number
of intracellular parasites detected after 48 h culture was reduced
by ≥90%, when compared to cultures with sporozoites incubated
inmedium without antibody (Figure 4A). Similar levels of sporo-
zoite neutralizing activity were detected in the serum of C57Bl/6
mice immunized with (NANP)6-OMPC/MAA (Figure 4B). The
level of inhibition observed with immune serum of BALB/c and
C57Bl/6 mice was comparable to that obtained when PfPb sporo-
zoites were incubated with 25µg/ml of MAB 2A10 specific for
P. falciparum CS repeats. Neutralizing activity was specific for P.
falciparum CS repeats, as MAB 3D11 specific for P. berghei CS
repeats did not inhibit PfPb sporozoite invasion. Control serum
frommice immunized with OMPC/MAAonly and serum of naïve
mice were not inhibitory.
Inhibition was dose-dependent, and lower levels of parasite
inhibition were detected at higher serum dilutions (Figure 4C).
Sera of 8/10 immunized C57Bl/6 mice gave ≥90% inhibition of
liver stage parasites at a 1:10 dilution, while sera of 5/10 immune
mice had neutralizing activity >90% at 1:20 dilution. One of
nine immune sera tested at 1:40 dilution gave >90% inhibi-
tion. Control MAB 3D11 and serum of mice immunized with
OMPC/MAA or naïve mice were not inhibitory at lowest dilution
tested (1:10).
SPOROZOITE NEUTRALIZING ANTIBODY In vivo
To determine if sporozoite neutralization in vitro correlated with
in vivo resistance to infection, the 10 (NANP)6-OMPC/MAA
immunized mice, along with similar number of OMPC/MAA
immunized control and naïve mice, were challenged by expo-
sure to the bites of PfPb-infected mosquitoes. Half of the mice
were sacrificed at 40 h post challenge to measure parasite levels in
the liver, while the other half were monitored for development of
blood stage parasites using daily blood smears.
Reduction of >90% of liver stage parasites relative to naïve
mice was detected in 5/5 challenged mice when liver extracts
were assayed by qPCR (Figure 5). In 4/5 of the (NANP)6-OMPC
immunized mice, the number of rRNA copies was below the
level of detection by qPCR (<100 18S rRNA copies). The para-
site burden in the liver of mice immunized with OMPC only was
lower than in naïve mice, suggesting potential non-specific innate
immune responses were elicited by OMPC, which is a known
TLR2 agonist (Latz et al., 2004) and/or the MAA adjuvant.
The in vitro sporozoite neutralization correlated with in vivo
resistance to sporozoite challenge (Table 1). The remaining
five immunized mice in the cohort challenged by bites of
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FIGURE 4 | Sporozoite meutralizing activity in murine immune serum.
Sera from (A) Balb/c or (B) C57Bl /6 mice immunized with three doses of
(NANP)6-OMPC/MAA were tested in TSNA. PfPb sporozoites, that express
P. falciparum CS repeats, were incubated with immune or control sera
(1:5 dilution) prior to addition to HepG2 cells. Levels of parasites in HepG2
cell extracts collected after 48h of culture were measured by qPCR. Results
are shown as mean number of parasite 18S rRNA copies in cell extracts,
based on an 18S rRNA plasmid standard. (C) Individual sera of 10 C57Bl/6
mice were tested in TSNA at dilutions of 1:10–1:40. Dotted line indicates
90% inhibition level.
FIGURE 5 | Parasite levels in murine liver following challenge by bites
of infected mosquitoes. Parasite 18S rRNA copy numbers in liver extract
obtained at 40h post challenge by bites of 5–15 PfPb-infected mosquitoes
was determined by qPCR. Results are shown for five mice in each group.
Table 1 | (NANP)6-OMPC immunized mice challenged by exposure to
malaria-infected mosquitoesa .
Experiment Group # Pos/total Protected% PPPb (Days)
I (NANP)6-OMPC 1+/5 80 7.0 –
OMPC 5+/5 0 5.0 (4–6)
Naive 5+/5 0 3.6 (3–4)
II (NANP)6-OMPC 3+/5 40 6.7 (6–8)
OMPC 5+/5 0 4.0 (3–5)
Naive 5+/5 0 3.8 (3–4)
aNaïve or immunized C57Bl/6 mice were challenged by exposure to bites of 18
mosquitoes infected with PfPb parasites expressing P. falciparum CS repeats.
bPrepatent period (PPP) is the first day blood stage parasites were detected by
microscopy in Giemsa stained daily blood smears.
PfPb-infected mosquitoes were monitored for development of
parasitemia by microscopic examination of daily Giemsa-stained
blood smears. No patent blood stage infection was detected in 4/5
immunized mice followed for 16 days post challenge, indicating
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sterile immunity was elicited by immunization with (NANP)6-
OMPC. The single (NANP)6-OMPC immunized mouse that
developed parasitemia had a delayed prepatent period of 7 days,
which was significantly prolonged compared to the five naïvemice
which all became patent 3–4 days post challenge. The sterile pro-
tection in these mice correlate with the low levels of parasite rRNA
detected in liver at 48 h post challenge in the qPCRmeasurements
carried out in the parallel cohort (Figure 5).
The development of protective immune responses in
(NANP)6-OMPC immunized mice was confirmed in a second
experiment, in which 2/5 of (NANP)6-OMPC immunized mice
remained negative after sporozoite challenge (Table 1). The
prepatent period in the immunized mice that developed blood
stage infection was 6.7 days, vs. 4.0 days for OMPC immunized
mice and 3.8 days for naive controls. The prolonged prepatent
period in the (NANP)6-OMPC immunized mice that developed
blood stage infection in Experiments 1 and 2, indicate that the
majority, but not all, of the infective sporozoites injected by the
mosquito were neutralized in vivo. Previous experiments using
intravenous injection of know numbers of parasites have shown
that elimination of >90% of sporozoites is required to obtain a
one day delay in developing a patent blood stage infection.
IMMUNOGENICITY OF (NANP)6-OMPC CONJUGATES IN RHESUS
MACAQUES
The kinetics and fine specificity of antibody responses in
an outbred non-human primate population, rhesus macaques,
was assessed following IM immunization with (NANP)6-
OMPC/MAA formulated with or without Iscomatrix® co-
adjuvant. In contrast to murine responses, the addition of
Iscomatrix® co-adjuvant was required for optimal antibody
responses in the rhesus macaques (Figure 6). Three rhesus
macaques injected with a single dose of (NANP)6-OMPC/
MAA + Iscomatrix® had GMT 65,020, while the three rhe-
sus macaques immunized with (NANP)6-OMPC/MAA had a log
FIGURE 6 | Kinetics of anti-repeat antibody response in rhesus
macaques. Groups of three adult rhesus macaques were immunized with
(NANP)6-OMPC/MAA with or without Iscomatrix® on days 0, 70, and 732
(arrows). Sera were collected at indicated time points and results are
shown as ELISA GMT using (NANP)3 peptide coated plates. The
concentration of repeat specific antibody (µg/ml) is shown for peak
responses post 1st and 2nd booster immunization.
lower anti-repeat antibody GMT 6,451. A booster injection of
(NANP)6-OMPC/MAA + Iscomatrix® on day 70, significantly
increased anti-repeat antibody titers 4-fold to GMT 260,080 (cor-
responding to 481µg/ml anti-repeat antibody). In marked con-
trast, in rhesus macaques immunized without Iscomatrix®, the
booster injection did not significantly increase antibody titer, with
8,127 GMT post boost as compared to 6,451 GMT post prime.
Persistence of high levels of anti-repeat antibody was also
dependent on presence of Iscomatrix® co-adjuvant. Anti-
repeat antibody titers in macaques immunized with (NANP)6-
OMPC/MAA + Iscomatrix® remained high for over 12 months,
with a gradual decrease to GMT 25,803 at one year, as com-
pared to GMT 202 in the absence of Iscomatrix®. Reactivity
with viable sporozoites expressing P. falciparum CS repeats was
also maintained in sera of rhesus macaques immunized with
(NANP)6-OMPC/MAA + Iscomatrix®. CSP titers of >1: 512
were obtained in pooled Day 84 sera, decreasing to 1:32 CSP titer
on Day 365 (data not shown).
At ∼2 years post immunization, rhesus macaques immu-
nized with (NANP)6-OMPC/MAA + Iscomatrix® had GMT
12,902 (19µg/mL anti-repeat antibody). A second booster
immunization with (NANP)6-OMPC/MAA + Iscomatrix®
delivered at this time point elicited strong anamnestic antibody
responses. At 1 month post the second boost, antibody levels in
the (NANP)6-OMPC/MAA+ Iscomatrix® immunized macaques
reached GMT 206,425 (318µg/ml anti-repeat antibody), compa-
rable to peak levels observed following first boost. In contrast,
at 2 years only low levels were present in rhesus macaques
immunized without Iscomatrix® (GMT 160). Following a boost
with (NANP)6-OMPC/MAA without Iscomatrix® at this time
point, no anamnestic response was observed with antibody titers
reaching levels observed post first dose, a log lower than lev-
els in the macaques immunized with (NANP)6-OMPC/MAA +
Iscomatrix®.
SPOROZOITE NEUTRALIZING ANTIBODY in vitro
The anti-repeat antibodies in the rhesus macaques immunized
with (NANP)6-OMPC/MAA + Iscomatrix® were functional
in vitro. Individual sera obtained post the 2nd dose (day 84)
had high levels of anti-repeat antibodies in all three rhesus
macaques, Rh 338, Rh 340, and Rh 342 (Figure 7A, black
bars). Corresponding with the presence of high levels of anti-
repeat antibodies, the immune sera of all three rhesus macaques
had >90% sporozoite neutralizing activity when tested at 1:5
dilution in the in vitro TSNA (Figure 7B, black bars).
Consistent with the ∼10-fold decrease in anti-repeat antibod-
ies at day 732, none of the rhesus macaques sera had sporozoite
neutralizing activity >90% at this time point (Figure 7A vs. 7B,
hatched bars). Importantly, administration of a 2nd booster
of (NANP)6-OMPC/MAA + Iscomatrix® on day 732 elicited
a strong anamnestic antibody response in all three macaques.
Serum obtained ∼1 month post the second boost (day 760) had
high levels of anti-repeat antibody that directly correlated with
recovery of sporozoite neutralizing activity (Figure 7A vs. 7B,
gray bars). The antibody titers and sporozoite neutralizing
activity in day 760 sera was comparable to peak levels observed
in day 84 sera following the first boost.
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FIGURE 7 | Sporozoite neutralizing activity in immune sera of rhesus
macaques. Sera was collected from three rhesus macaques at days 0,
84, 732, and 760 post immunization with (NANP)6-OMPC/MAA +
Iscomatrix®. (A) Sera were tested in ELISA with results shown as
anti-repeat GMT. (B) TSNA was carried out using 1:5 serum dilution with
results shown as mean % Inhibition of PfPb sporozoite invasion of HepG2
cells.
Limitations on the number of rhesus macaques available
precluded inclusion of an OMPC/MAA only group. In order to
rule out non-specific inhibitory effects in the rhesus macaques
serum, peptide competition TSNA were carried out to determine
if sporozoite neutralizing activity was specific for P. falciparum
CS repeats. Pre-incubation of rhesus macaques immune sera with
various concentrations of (NANP)3 repeat peptide was found to
block sporozoite neutralizing activity in a dose dependent man-
ner (Figure 8). In Rh 340, immune sera obtained +14 d post first
boost (day 84) had 1:10 titer of sporozoite neutralizing activity in
the absence of competitor peptide (open bar). Pre-incubation of
the immune serum with 20µg/ml (NANP)3 competitor peptide
reduced inhibition to levels observed in Day 0 serum (black bar).
There was a dose-dependent increase in sporozoite neutralizing
activity with lower concentrations of competitor peptide. Rh 340
immune serum incubated with 0.2µg/ml of (NANP)3 competitor
peptide gave >90% inhibition of sporozoite invasion of HepG2
cells, similar to sporozoite neutralizing activity in immune serum
in the absence of competitor peptide.
FIGURE 8 | Peptide competition TSNA. Rhesus macaque #340 (Rh 340)
serum from Days 0 and 84 was tested at 1:10 dilution. Serum from Rhesus
macaque #342 (Rh 342) obtained on Days 0 and 760 was tested at 1:20
dilution. Serum was pre-incubated with 10-fold dilutions of (NANP)3
competitor peptide prior to addition of PfPb sporozoites and completion of
TSNA. Day 0 serum was tested with and without 20µg/ml of (NANP)3
peptide competitor.
Similarly, Rh 342 immune serum obtained on Day 760, ∼1
month post the second boost with (NANP)6-OMPC/MAA +
Iscomatrix®, had high levels of sporozoite neutralizing activity
at 1:20 dilution in the absence of competitor peptide (open bar).
Pre-incubation of Day 760 immune serum with either 20µg/ml
or 2µg/ml of (NANP)3 competitor peptide reduced inhibition
to 5% and 20%, similar to day 0 serum. At low doses of com-
petitor peptide, 0.2µg/ml, sporozoite neutralizing activity was
not blocked and percent inhibition was comparable to Day 760
immune serum without competitor peptide.
DISCUSSION
In the current study, the (NANP)6-OMPC conjugate adsorbed to
MAA was found to be highly immunogenic in two inbred strains
of mice, Balb/c and C57Bl/6, and in out-bred rhesus macaques.
The high levels of anti-repeat antibodies elicited in mice and
rhesus macaques correlated with functional antibody that cross-
linked surface CS protein in the CSP reaction and inhibited sporo-
zoite invasion of hepatoma cells in vitro. These assays demonstrate
the ability of antibodies elicited by (NANP)6-OMPC immuniza-
tion to recognize CS repeats on the viable sporozoite and block
motility required for invasion of host cells in vitro (Cochrane
et al., 1976; Stewart et al., 1986).
Although the transgenic P. berghei parasites express P. fal-
ciparum CS repeats, they remain a rodent parasite biologi-
cally and thus allow comparison of inhibition in vitro with
functional sporozoite neutralizing activity in vivo. (NANP)6-
OMPC/MAA immunized mice with high levels of inhibitory
antibodies in the in vitro assay, had significantly reduced para-
site levels in the liver at 48 h post challenge exposure to the bites
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of PfPb infected mosquitoes. Moreover, the reduced parasite lev-
els in the liver of immunized mice correlated with absence, or
delayed, blood stage infection, as measured in Giemsa-stained
blood smears. Partial protection in several of the challenged
immunized mice was reflected in increased pre-patent periods,
indicating that majority but not all infective sporozoites were
neutralized.
Anti-repeat antibodies function in vivo by immobilizing
sporozoites in the skin and preventing entrance into the blood
circulation and transit to the liver and/or hindrance of CS interac-
tion with host liver cells required for invasion (Cerami et al., 1992,
1994; Vanderberg and Frevert, 2004). Thus, a key goal of vaccine
development is the identification of adjuvant and delivery sys-
tems to produce high levels of anti-repeat antibodies. While mice
gave optimal responses with alum adsorbed peptide conjugate,
Iscomatrix® was required as co-adjuvant for optimal antibody
responses in non-human primates. Rhesus macaques immunized
with (NANP)6-OMPC/MAA+ Iscomatrix® had a log higher titer
of anti-repeat antibodies compared to rhesus macaques immu-
nized with (NANP)6-OMPC/MAA. The antibodies elicited by
two doses of (NANP)6-OMPC/MAA + Iscomatrix® were long-
lived and could be detected for ∼2 years post immunization.
Encouragingly, a booster immunization at day 732 increased anti-
body to levels observed post 2nd dose. In contrast, in the absence
of Iscomatrix® co-adjuvant, the anti-repeat antibodies were logs
lower in magnitude, did not give secondary responses and
declined rapidly to near background levels. Similar strong adju-
vant requirements were noted in rhesus macaques immunized
with an influenza peptide conjugate, M2e-OMPC, formulated in
MAA plus QS21, as compared to MAA only (Fan et al., 2004).
Consistent with the murine studies (Figure 4), the presence of
high levels of anti-repeat antibody in rhesus macaques immu-
nized with (NANP)6-OMPC/MAA + Iscomatrix® correlated
with sporozoite neutralizing activity in the TSNA. All three rhe-
sus macaques had neutralizing activity >90% at 1:5 dilution in
sera obtained post the first boost, and 2/3 rhesus macaques had
neutralizing titers of 1:20. The presence of sporozoite neutralizing
activity in serum post the first boost (day 84) and second boost
(day 760), directly correlated with the presence of high titers of
anti-repeat antibody, with 481µg/ml and 318µg/ml, respectively.
Inhibition was specific for P. falciparum CS repeats, as pre-
incubation of rhesus macaques immune serum with (NANP)3
competitor peptide led to loss of sporozoite neutralizing activity
in TSNA.
Recent clinical studies of CS subunit vaccines have found
an association of high anti-repeat antibody titers and resis-
tance to sporozoite challenge, although a threshold level of pro-
tective antibody has not been identified. In two recent Phase
I/II trials of the CS-based RTS,S vaccine, immunized malaria-
naïve volunteers who developed sterile immunity following
P. falciparum sporozoite challenge had significantly higher con-
centrations of anti-repeat antibody (114–188µg/ml) and mul-
tifunctional CD4 + T cells when compared to non-protected
individuals (30–73µg/ml) (Kester et al., 2008, 2009). While
direct comparison are difficult, the preclinical studies in mice
and rhesus macaques of RTS,S in various adjuvant formulations
gave levels of anti-repeat antibodies that were lower and less
persistent than antibodies elicited by (NANP)6-OMPC/MAA ±
Iscomatrix®. Mice immunized with RTS,S, in either the AS02
adjuvant (QS21, MPL in oil-in-water emulsion) or AS01 adju-
vant (in which liposomes replace the oil-in-water component),
developed peak anti-repeat antibody of ∼6 × 104 GMT in ELISA
using the R32 recombinant protein as antigen (Mettens et al.,
2008). In rhesus macaques, two doses of RTS,S, formulated in
either the AS01 or AS02 adjuvant, elicited peak anti-repeat GMT
∼1.5 × 103, which decreased to near background by 8 weeks post
boost. Following a second boost with RTS,S in either adjuvant,
GMT rose to peak titers observed post the first boost, returning
to near background at 22 weeks.
The current studies demonstrate that the magnitude and per-
sistence of the anti-repeat response in mice and rhesus macaques
immunized with two doses of (NANP)6-OMPC/MAA ±
Iscomatrix® was significantly higher (1 × 105) and more long-
lived (∼2 years) than those observed following RTS,S immu-
nization. The kinetics, magnitude, and persistence of anti-repeat
antibodies in mice and rhesus macaques immunized with
(NANP)6-OMPC are consistent with results of our previous stud-
ies with a P. falciparum Transmission Blocking Vaccine (TBV)
(Wu et al., 2006). This vaccine, comprised of a recombinant sex-
ual stage protein, Pfs25, conjugated to OMPC and adsorbed to
MAA, elicited high levels of functional antibody in mice and rhe-
sus macaques that inhibited oocyst formation in the mosquito
midgut. Anti-Pfs25 antibodies persisted for 18 months in rhe-
sus macaques and could be boosted by injection of recombinant
Pfs25 protein. Following the second boost, the anamnestic anti-
body responses reached peak titers similar to those obtained
after the first boost, as found also for anti-repeat antibodies
in the (NANP)6-OMPC/MAA+Iscomatrix® immunized rhesus
macaques (Figure 6).
The enhanced immunogenicity of these malaria-OMPC con-
jugates may reflect unique OMPC interactions with the innate
immune system. The vesicular structure of OMPC provides a par-
ticle with diameter 100–200 nm to enhance uptake by dendritic
cells. OMPC is also a known TLR2 agonist, related to the presence
in OMPC of porin proteins from the surface of N. meningitidis
that has been shown to induce DC activation and maturation
(Massari et al., 2002; Latz et al., 2004). In addition, the response to
repeat peptide in humanvolunteers is known tobedosedependent
and OMPC has a large capacity for peptide chemical conjugation,
with ∼3,700 mol/mol for (NANP)6-OMPC as compared to the
expected lower capacity for (NANP)3-TT used in the first clini-
cal trials of a synthetic peptide vaccine (Herrington et al., 1987).
Adsorptionof thepeptide conjugates to alumadjuvantmay further
increase the immunogenicity of the OMPC based conjugates, by
stimulating innate immune responses through NLRP3 inflamma-
some (Eisenbarth et al., 2008; Li et al., 2008). The combination of
enhanced uptake by DC, innate immune signaling through TLR
and/or inflammasome, and high density of the malaria epitope,
may contribute to strong humoral responses in mice.
In contrast to mice, the (NANP)6-OMPC/MAA formulation
was not optimal for rhesus macaques. Induction of high levels
of long-lived anti-repeat antibody in macaques required inclu-
sion of a co-adjuvant, Iscomatrix®. The (NANP)6-OMPC/MAA+
Iscomatrix® formulation elicited titers 2 logs higher than the
Frontiers in Cellular and Infection Microbiology www.frontiersin.org November 2012 | Volume 2 | Article 146 | 9
Przysiecki et al. P. falciparum CS peptide-OMPC vaccine
MAA only formulation, and these antibodies persisted for ∼2
years. Iscomatrix® is a particulate adjuvant, comprised of
cholesterol, phospholipid, and saponin, which has been shown
to be safe in a series of clinical trials of cancer and viral vac-
cines (Sun et al., 2009; McKenzie et al., 2010). The requirement
for stronger adjuvant formulation in rhesus macaques as com-
pared to mice has been found in other studies. In general, a lower
immunogenicity of malaria subunit vaccines has been observed
in non-human primates. We have found that a stronger oil-based
adjuvant was required for optimal immunogenicity of a CS virus-
like particle (VLP) vaccine in rhesus macaques as compared to
murine studies (Langermans et al., 2005). However, the formula-
tion of VLP in stronger oil-in-water adjuvants was associated with
unacceptable reactogenicity, with sterile abscesses developing in
the immunized rhesus macaques. No reactogenicity was noted
in rhesus macaques immunized with (NANP)6-OMPC/MAA +
Iscomatrix® in the current studies.
The OMPC carrier has a strong safety record based on its
use as carrier in an H. influenzae type b (Hib) pediatric vac-
cine, PedvaxHIB®, which is comprised of H. influenzae capsular
polysaccharide conjugated to OMPC and adsorbed to MAA. Hib
vaccine has been delivered to millions of infants 2–71 months old
to prevent childhood bacterial meningitis. The well-established
safety record of OMPC as carrier protein is particularly impor-
tant, as the target population for a malaria vaccine is infants
<5 years who suffer the majority of the mortality and morbidity
caused by P. falciparum infection. While PedvaxHIB® vaccination
can elicit anti-carrier antibodies that could potentially modulate
immune responses to a (NANP)6-OMPC vaccine, we found com-
parable malaria-specific antibody responses induced in mice with
and without pre-existing anti-OMPC antibodies. Moreover, the
presence of pre-existing anti-OMPC antibodies did not inhibit
sporozoite elicited anamnestic anti-repeat antibody responses
in (NANP)6-OMPC immunized mice, suggesting that parasite-
specific memory B cells were also not affected. These studies
also suggest that antibody responses induced by (NANP)6-OMPC
immunization can potentially be boosted by natural exposure to
malaria infected mosquitoes in endemic areas.
The studies in mice and rhesus macaques demonstrate that
OMPC conjugated to a large malaria recombinant protein
(Pfs25H,MW 20 kDa) as well as a lowmolecular weight (NANP)6
peptide can elicit high levels of long-lived functional antibod-
ies that inhibit parasite development in vitro and in vivo. The
combination of both Pfs25 and (NANP)6-OMPC conjugates in
a vaccine could prevent transmission of parasites both to the
mammalian host and to the mosquito vector. Combination vac-
cines would be particularly effective in malaria control programs,
as parasites that evaded the immune responses targeting sporo-
zoites could be prevented from spreading to the mosquito vector.
The OMPC carrier would also be amendable to conjugation with
other malaria antigens that are targeted by antibody-mediated
immunity, e.g., antigens of asexual blood stages that cause clini-
cal disease, to provide multi-antigen vaccines that target all stages
of the complex Plasmodium life cycle. The current and previ-
ous studies in immunized mice of different MHC haplotype and
a non-human primate species suggests that OMPC conjugates
may lead to new vaccine candidates for control and eventual
eradication/elimination of malaria.
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